^
Association details:
| Biomarker: | PPFIBP2-BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion
Excerpt:
At this time, in April2014, a PPFIBP2-BRAFfusion was discovered in DNA extracted from a resected brain metastasis...Trametinib2mg once-daily was commenced as a single agent, and after three weeks the anemia had resolved and performance status improved (ECOG 1). Progress imaging at week 6 demonstrated a 90% reduction in extracranial metastases (sum of diameters of all metastases, from181mm to 19mm), and 19% reduction in intracranial metastases (from 64mm to 52mm).
DOI:
10.1111/pcmr.12388
